UNDER THE AUSPICES

Associazione Italiana di Oncologia Medica

European Society for Medical Oncology

Intergruppo Melanoma Italiano
Recent insights into the genetic and somatic aberrations have initiated a new era of rapidly evolving targeted and immune-based treatments for melanoma. After decades of unsuccessful attempts to finding a more effective cure in the treatment of melanoma now we have several drugs active in melanoma. The possibility to use these drugs in combination to improve responses to overcome the resistance, to potentiate the action of immune system with the new immunomodulating antibodies, and identification of biomarkers that can predict the response to a particular therapy represent new concepts and approaches in the clinical management of melanoma.

In order to disclose and stimulate the discussion of new approaches and strategies in the field of melanoma, more than 40 international faculty members are now joining “Melanoma Bridge 2013”. After the first meeting “Melanoma Research: a bridge Naples-USA” (Naples, December 6-7th 2010), the second edition “Melanoma Research: a bridge from Naples to the World” (Naples, December 5-6th 2011), and the third “Melanoma Bridge 2012”, the 2013 Congress will take place from December 5th to 8th in Naples, jointly organized by Istituto Nazionale Tumori Fondazione “G. Pascale” and Fondazione Melanoma Onlus, together with the Society for ImmunoTherapy of Cancer (SITC) and Sidra Medical and Research Center (Doha, Qatar).

Presidents of the event are Paolo A. Ascierto (INT, Naples, Italy), Francesco M. Marincola (Sidra Center, Doha, Qatar), and Nicola Mozzillo (INT, Naples, Italy), now gathering with the international faculty members in an interactive atmosphere which stimulated discussion and exchange of their experience regarding the most recent advances in research and clinical management of melanoma patients.

This year new topics of discussion have been identified with special emphasis on latest findings in melanoma research and advances: Diagnosis and new procedure, Molecular advances and combination therapies, News in immunotherapy, Tumor microenvironment and biomarkers. On December 8th the experts will share a round table focusing on immunoscoring technique and, subsequently, a second round table on Regulatory Issues on Melanoma Drugs.
GENERAL INFORMATION

**CME PROVIDER AND ORGANISING AGENCY:**
3P Solution Srl
Via Marradi 3, 20123 Milan
Phone +39 02 36631574
Fax +39 02 89098927
Cell. +39 3496485434
www.3psolution.it
info@3psolution.it
info@melanomabridge.org

**OFFICIAL LANGUAGE:**
The official language is English

**REGISTRATION:**
Only registered attendees will be admitted to the meeting.
The registration fee includes:
- participation in the scientific program
- CME credits
- coffee breaks and lunches from December 6th to 8th
- congress bag

Participants are kindly requested to inform us about any dietary habit (i.e. food allergies/intolerances, vegetarian or vegan habits).

Please register at 3P Solution desk (cash or credit card accepted).
GENERAL INFORMATION

CONGRESS VENUE:
Royal Continental Hotel
Via Partenope, 38-44
80121 - Naples
Phone +39 081 245 2068
www.royalgroup.it/royalcontinental/
CONTINUING MEDICAL EDUCATION

3P Solution has been accredited by the Ministry of Health as a CME Provider (code 327) and has a quality-management system that meets the requirements of UNI EN ISO 9001:2008, with CSQA certificate no. 23887.

Melanoma Bridge is accredited by the Italian Ministry of Health for 20 CME credits. The specialties eligible for CME credits are: Medical Doctors, Pharmacists, Biologists, and Nurses.

In order to receive credits, participants must:

1. Attend all the accredited sessions;
2. Complete the assessment test at the end of the congress (a grade of 75% must be obtained to receive CME credit);
3. Complete the evaluation questions at the end of the congress.

CME certificate attendance will be sent to the participants at the end of the evaluation procedure.
Melanoma Bridge 2013

SCIENTIFIC PROGRAM
17.00 Opening Ceremony**
Nicola Mozzillo, Francesco M. Marincola

17.10 In ricordo di un amico: Natale Cascinelli**
In memory of a friend: Natale Cascinelli
Nicola Mozzillo, Paolo A. Ascierto

17.30 Stato dell’Arte e nuove prospettive**
State of the Art and new perspectives
Paolo A. Ascierto

17.45 L’impegno della Fondazione Melanoma**
The commitment of the Fondazione Melanoma
Antonio Brancaccio (Responsabile Area Pazienti, Fondazione Melanoma)

18.00 Melanoma and the role of patient advocacy**
Valerie Guild

18.30 Presentazione attività 2014 Fondazione Melanoma**
Presentation of the Fondazione Melanoma activities 2014

18.45 Award Ceremony**

È prevista la traduzione simultanea
Simultaneous translation will be provided

* Invited speaker
** Not included in the CME accredited program
**DIAGNOSIS AND NEW PROCEDURES**

*Chair: Jeffrey Gershenwald, Nicola Mozzillo*

9.30  The role of melanoma genetic testing in prevention and early detection  
Sancy Leachman

9.55  How should melanoma patients be followed-up?  
Clause Garbe

10.20  Clinically important data from gene microarray studies of melanocytic lesions  
Alistair Cochran

10.45  AJCC classification, the Melanoma Cancer Genome Atlas Program (TCGA), 
and beyond: Integrated models in the molecular era  
Jeffrey Gershenwald

11.10  Break

11.25  Combination therapies and Surgery in the treatment of metastatic melanoma  
Nicola Mozzilo

11.50  Diagnosis and new procedures: innovation and sustainability  
Alessandro Testori

12.15  Are there systemic benefits to local and regional therapy of metastases in melanoma?  
Mark Faries

12.40  Discussion on the best abstracts on diagnosis and new procedures  
Jeffrey Gershenwald, Nicola Mozzillo

  Revealing cancer initiating cells in metastatic melanomas by harnessing the host’s anti tumor humoral immune mechanisms presented by Beatrix Kotlan

  Activation of the ErbB3-AKT axis promotes melanoma cell survival and proliferation in response to RAF/MEK inhibition presented by Luigi Fattore

13.00  Lunch & Poster Session  **  

**Not included in the CME accredited program**
MOLECULAR ADVANCES AND COMBINATION THERAPIES

Chair: Paolo A. Ascierto, Giuseppe Palmieri

14.00 Melanoma next-generation sequencing, biological significance and clinical applications
Ruth Halaban

14.25 Biological and clinical implications of cell signaling in melanoma
Richard Marais

14.50 Targeting apoptosis to enhance the effectiveness of BRAF-directed therapy in melanoma
Ryan Sullivan

15.15 CSF-1 and Erk inhibitors for melanoma
Antoni Ribas

15.40 Break

16.05 Recent advances in melanoma combination therapy
Igor Puzanov

16.30 Combination Therapies: The Solution to Drug Resistance?
James Larkin

16.55 LGX818 + MEK162 combination therapy of melanoma and beyond BRAFi/MEKi
Richard Kefford

17.20 Discussion on the best abstracts on Molecular advances and Combination Therapies
Paolo A. Ascierto, Giuseppe Palmieri

Assessment of germline and somatic alterations in main candidate genes among patients with multiple primary melanoma presented by Maria Colombino

Regulation of melanoma initiating cells by Hedgehog signaling and SOX2, presented by Barbara Stecca
Combination therapy with ipilimumab and electrochemotherapy: preliminary efficacy results and correlation with immunological parameters presented by Ester Simenone

Efficacy of Radiotherapy in patients on progression after treatment with ipilimumab 3 mg/kg presented by Antonio M. Grimaldi

Updated results and correlative FDG-PET analysis of a phase IB study of vemurafenib and cobimetinib (MEK inhibitor [GDC-0973]), in advanced BRAFV600- mutated melanoma (BRIM7) presented by Igor Puzanov

18.20 Closing remarks and summing up for the next day
NEWS IN IMMUNOTHERAPY

Chair: Michele Maio, Giuseppe Masucci

9.20 Award lecture of Fondazione Melanoma: New Approaches to Adjuvant Therapy Adjuvant Therapy
John M. Kirkwood

9.50 Escape mechanisms in melanoma
Soldano Ferrone

10.15 Understand variants contribute to immune responsiveness
Ena Wang

10.40 Distinct strategies of melanoma to evade immune surveillance and induce resistance to targeted therapies
Barbara Seliger

11.05 Break

11.20 Targeting the Tim-3 pathway in cancer
Ana Carrizosa Anderson

11.45 Combinations of Immunotherapy
F. Stephen Hodi

12.10 Recent Advances in Adoptive T Cell Therapies
David Stroncek

12:35 Discussion on the best abstracts on News in immunotherapy
Michele Maio, Giuseppe Masucci

Peripheral and tumor immune correlates in patients with advanced melanoma treated with nivolumab (anti-PD-1, BMS-936558, ONO-4538) monotherapy or in combination with ipilimumab presented by Michael A. Postow

Ipilimumab treatment results in an early decrease in the frequency of circulating granulocytic myeloid derived suppressor cells as well as their arginase1 production presented by Giusy Gentilcore
Harnessing host innate immunity may combat acquired resistance to BRAFi presented by Francesco Colucci

Regulated intratumoral expression of IL-12 as a basis for combination therapy in melanoma presented by Jonathan Lewis

13.30 Lunch & Poster Session**

** Not included in the CME accredited program
TUMOR MICROENVIRONMENT AND BIOMARKERS
Chair: Magdalena Thurin, Gennaro Ciliberto

14.30 Signature genes and molecular biomarkers of melanoma predisposition to prometastatic effects of inflammation
Fernando Vidal-Vanaclocha

14.55 Immunotherapies based on CD137
Ignacio Melero

15.20 Inflammation in tumor progression
Alberto Mantovani

15.45 Immunoprofiling responders to immunotherapy
Carlo Bifulco

16.10 Break

16.25 New candidate biomarkers for cytokine and ipilimumab activity
Alexander Eggermont

16.50 Mechanisms mediating a T cell-inflamed versus non-inflamed melanoma tumor microenvironment
Thomas F. Gajewski

17.15 Immunological consequences of BRAF inhibitor treatment
Bastian Schilling

17.35 Immune gene expression patterns in primary melanoma tumors predict clinical outcomes
Yvonne Saenger

17.50 Discussion on the best abstracts on Tumor Microenvironment and Biomarkers
Magdalena Thurin, Gennaro Ciliberto

Biomarker analysis of on-treatment and at progression biopsies from BRIM7 - a phase 1B trial of combined vemurafenib and cobimetinib treatment in BRAF V600 mutated melanoma presented by Antoni Ribas
Systems biology analysis of immune signaling in peripheral blood mononuclear cells (PBMC) of melanoma patients receiving ipilimumab; basis for response biomarker identification presented by Rachael Hawtin

18.30 Closing remarks and summing up for the next day
WORLD-WIDE IMMUNOSCORE TASK FORCE: AN UPDATE
Francesco M. Marincola, Paolo A. Ascierto

9.00 Immunosenone participants round table on recent advances

The importance of the Immunosenone for cancer classification, and give an update on the French cohort from the worldwide Immunosenone consortium
Jerome Galon

The Medical Need for an Immune Scoring/Profiling for Melanoma and Other Cancer Patients
Paolo A. Ascierto

Gene expression profiling versus IHC to identify an active T cell-infiltrated melanoma microenvironment
Thomas Gajewski

Loss of HLA molecules as melanoma resistance mechanism in immune checkpoint blockade therapy
Andrea Anichini

Update on definien’s Immunosenone module/plugin and on the status of Portland’s Immunosenone consortium’s cohort
Carlo Bifulco

Using NanoString technology to develop strategies to enhance the immunosenone
Yvonne Saenger

Update on the status of the project in the middle-eastern countries
Lotfi Chouchane

HLA-G identification and genus dependent HLA_A2 prognostic relevance in colon cancer cases participating to the immunosenone project
Giuseppe Masucci

11.15 Break
**REGULATORY SESSION**

Pier Luigi Canonico, Sabino De Placido*

11:30 Round Table on Regulatory issues of Melanoma drugs

Paolo A. Ascierto  
(*Unit of Melanoma, Cancer Immunotherapy and Innovative Therapy, Istituto Tumori Fondazione Pascale, Naples, Italy*)

Antonio Brancaccio  
(*Fondazione Melanoma*)

European Cancer Patients Coalition: an innovative approach to face melanoma  
Francesco De Lorenzo (*President of European Cancer Patient Coalition, ECPC*)

New drugs for melanoma: are they sustainable?  
Luca Pani (*General Director of the Italian Medicines Agency, AIFA*)

Carmine Pinto  
(*President Elect of the Italian Association of Medical Oncology, AIOM*)

Paola Queirolo*  
(*President Elect of the Italian Melanoma Intergroup*)

Carlo Riccardo Rossi*  
(*President of the Italian Melanoma Intergroup*)

Francesco Rossi  
(*President of the Italian Society of Pharmacology, SIF*)

13:30 Closing remarks

13:45 CME test
POSTER SESSION

DECEMBER 6TH / 7TH 2013 Lunch Area First Floor

DIAGNOSIS AND NEW PROCEDURES

1. Long-term response after electrochemotherapy in patients with relapsed or refractory cutaneous melanoma
   Ugo Marone et al.

2. A novel approach to target metastases of melanoma cells in an organ-selective manner
   Donna L. Senger et al.

3. UV exposure and melanoma prognostic factors: results from Clinical National Melanoma Registry
   Maurizio Montella et al.

4. Psychological features in lower risk melanoma: an analysis on 204 patients
   Simone Ribero et al.
MOLECULAR ADVANCES AND COMBINATION THERAPIES

5. Phase Ib/II, open-label, dose-escalation study of LGX818, an oral selective BRAF inhibitor, in combination with MEK162, an oral MEK1/2 inhibitor, in patients with BRAF V600-dependent advanced solid tumors: Preliminary results
Richard Kefford et al.

6. In vivo targeting of cutaneous melanoma using an MSH-engineered human protein cage bearing fluorophore and MRI tracers
Cristina Maria Failla et al.

Amalia Azzariti et al.

8. Overall survival of patients with chemotherapy-naive advanced melanoma treated with ipilimumab 3 mg/kg in clinical trials
Reinhard Dummer et al.

9. The mitochondrial master regulator gene PGC1alpha in novel sporadic melanoma cell lines: correlations with BRAF mutational status
Gabriella Guida et al.
TUMOR MICROENVIRONMENT AND BIOMARKERS

10. Enrichment of KIR+CD57+ highly cytotoxic NK cells in sentinel lymph nodes of melanoma patients
   Ennio Carbone et al.

11. MISIPI study: Melanoma ImmunoScore evaluation in patients treated with IPIlimumab
    Carlo Bifulco et al.

12. hMENA splicing program impacts the clinical outcome of early stage lung cancer patients. How and why?
    Paola Nisticò et al.

13. Natural immunomodulator preimplantation factor (PIF) affects cancer growth in malignant melanomas
    Beatrix Kotlan et al.
Paolo A. Ascierto
Unit of Melanoma, Cancer Immunotherapy and Innovative Therapy, Istituto Tumori Fondazione Pascale, Naples, Italy

Francesco M. Marincola
Chief Research Officer, Sidra Medical and Research Centre, Doha, Qatar

Nicola Mozzillo
Director of the Department Melanoma and Soft Tissues, Istituto Tumori - Fondazione G. Pascale, Naples, Italy
Paolo A. Ascierto  
Unit of Melanoma, Cancer Immunotherapy and Innovative Therapy, Istituto Tumori Fondazione Pascale, Naples, Italy

Lotfi Chouchane  
Assistant Dean for Basic Science, Professor of Genetic Medicine, Professor of Microbiology & Immunology, Weill Cornell Medical College, Qatar

Gennaro Ciliberto  
Scientific Director of the National Cancer Institute “Fondazione G. Pascale” of Naples, Italy

Clause Garbe  
University Professor of Dermatology, Head, Division of Dermatologic Oncology Department of Dermatology Eberhard Karls University Tuebingen (Stuttgart), Germany

John M. Kirkwood  
Usher Professor of Medicine, Dermatology, and Translational Science University of Pittsburgh School of Medicine Director, Melanoma and Skin Cancer Program University of Pittsburgh Cancer Institute

Alberto Mantovani  
Scientific Director of Istituto Clinico Humanitas, Milan, Italy

Francesco M. Marincola  
Chief Research Officer, Sidra Medical and Research Centre, Doha, Qatar

Giuseppe Masucci  
Professor, Department of Oncology-Pathology, and KcRN, Karolinska Institutet and Karolinska University Hospital, Stockholm, Sweden

Ignacio Melero  
Professor of Immunology and Consultant, CIMA, CUN and Medical School, University of Navarra, Pamplona, Spain

Nicola Mozzillo  
Director of the Department Melanoma and Soft Tissues, Istituto Tumori - Fondazione G. Pascale, Naples, Italy

Giuseppe Palmieri  
Unit of Cancer Genetics, Institute of Biomolecular Chemistry, National Research Council, Sassari, Italy
Antoni Ribas
Professor of Medicine, Surgery, and Molecular and Medical Pharmacology at the University of California Los Angeles, California

David Stroncek
Chief, Cell Processing Section, Department of Transfusion Medicine, NIH Clinical Center, Bethesda, Maryland

Magdalena Thurin
Program Director, Cancer Diagnosis Program, Division of Cancer Treatment and Diagnosis, NCI, NIH, Rockville, Maryland

Walter Urba
Director cancer research, Earle A. Chiles Research Institute, Providence Cancer Center, Providence, Oregon

Fernando Vidal-Vanaclocha
Professor of Cell Biology and Human Histology, Vice Dean for Research and International Affairs and Scientific Director of the Institute of Applied Molecular Medicine (IMMA) at the CEU-San Pablo University School of Medicine, Madrid, Spain

Ena Wang
Acting Section Head of Infectious Disease and Immunogenetics Section (IDIS); Director of Molecular Science, Department of Transfusion Medicine, CC; Associated director of Center for Human Immunology, NIH, Maryland
Paolo A. Ascierto  
Unit of Melanoma, Cancer Immunotherapy and Innovative Therapy, Istituto Tumori Fondazione Pascale, Naples, Italy

Carlo Bifulco  
Earle A. Chiles Research Institute, Robert W. Franz Cancer Research Center, Providence Portland Medical Center, Portland, Oregon

Pier Luigi Canonico  
Department of Scienze del Farmaco, University of Piemonte Orientale, Novara, Italy

Ana Carizzosa Anderson  
Assistant Professor at Kuchroo Laboratory, Center for Neurologic Disease Brigham and Women’s Hospital, Harvard Medical School, Boston, Massachusetts

Lotfi Chouchane  
Assistant Dean for Basic Science, Professor of Genetic Medicine, Professor of Microbiology & Immunology, Weill Cornell Medical College, Qatar

Gennaro Ciliberto  
Scientific Director of the National Cancer Institute “Fondazione G. Pascale” of Naples, Italy

Alistair Cochran  
Distinguished Professor of Pathology and Laboratory Medicine, UCLA, California

Francesco De Lorenzo  
President of Italian Federation of Volunteer-based Cancer Organizations, FAVO

Sabino De Placido*  
Professor of Medical Oncology, University of Naples, Italy

Alexander Eggermont  
Institut de Cancérologie Gustave Roussy, Villejuif, Paris-Sud, France

Mark Faries  
Department of Surgical Oncology, John Wayne Cancer Institute at Saint John’s Health Center, Santa Monica, California

Soldano Ferrone  
University of Pittsburgh, Department of Pathology and University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania
Thomas F. Gajewski  
Department of Pathology and Department of Medicine, Section of Hematology/Oncology,  
Chicago, Illinois

Jerome Galon  
Research Director at INSERM (National Institute of Health and Medical Research), Paris,  
France

Clause Garbe  
University Professor of Dermatology, Head, Division of Dermatologic Oncology Department  
of Dermatology Eberhard Karls University Tuebingen (Stuttgart), Germany

Jeffrey E. Gershenwald  
Professor, Department of Surgical Oncology, Division of Surgery, The University of Texas  
MD Anderson Cancer Center, Houston, Texas

Ruth Halaban  
Director, Yale SPORE in Skin Cancer, Yale University School of Medicine, Department of  
Dermatology, New Haven, Connecticut

F. Stephen Hodi  
Dana-Farber Cancer Institute, Boston, Massachusetts

Richard Kefford  
Professor of Medicine and Director of the Westmead Institute for Cancer Research and  
Consultant Medical Oncologist to the Sydney Melanoma Unit and the NSW Breast Cancer  
Institute, Sydney, Australia

John M. Kirkwood  
Usher Professor of Medicine, Dermatology, and Translational Science University of  
Pittsburgh School of Medicine Director, Melanoma and Skin Cancer Program University of  
Pittsburgh Cancer Institute

James Larkin  
Department of Medicine, The Royal Marsden Hospital, London, UK

Sancy Leachman  
Professor and Chair, Department of Dermatology, Oregon Health & Sciences University

Michele Maio  
U.O.C. Immunoterapia Oncologica Azienda Ospedaliera Universitaria Senese, Siena, Italy

Alberto Mantovani  
Scientific Director of Istituto Clinico Humanitas, Milan, Italy
Richard Marais  
Director, Paterson Institute for Cancer Research, Manchester, United Kingdom

Francesco M. Marincola  
Chief Research Officer, Sidra Medical and Research Centre, Doha, Qatar

Giuseppe Masucci  
Professor, Department of Oncology-Pathology, and KcRN, Karolinska Institutet and Karolinska University Hospital, Stockholm, Sweden

Ignacio Melero  
Professor of Immunology and Consultant, CIMA, CUN and Medical School, University of Navarra, Pamplona, Spain

Nicola Mozzillo  
Director of the Department Melanoma and Soft Tissues, Istituto Tumori - Fondazione G. Pascale, Naples, Italy

Giuseppe Palmieri  
Unit of Cancer Genetics, Institute of Biomolecular Chemistry, National Research Council, Sassari, Italy

Luca Pani  
General Director, Italian Medicines Agency - AIFA

Carmine Pinto  
President Elect of Associazione Italiana di Oncologia Medica, AIOM

Igor Puzanov  
Associate Professor of Medicine, Clinical Director, Renal Cancer/Melanoma, Vanderbilt University, Nashville, Tennessee

Antoni Ribas  
Professor of Medicine, Surgery, and Molecular and Medical Pharmacology at the University of California Los Angeles, California

Yvonne Saenger  
Departments of Dermatology, Mount Sinai School of Medicine, New York

Bastian Schilling  
Department of Dermatology, University Hospital Essen, Essen, Germany
Barbara Seliger  
Institute of Medical Immunology, Martin-Luther-University Halle-Wittenberg, Halle, Saale, Germany

David Stroncek  
Chief, Cell Processing Section, Department of Transfusion Medicine, NIH Clinical Center, Bethesda, Maryland

Ryan Sullivan  
Massachusetts General Hospital Cancer Center, Boston, Massachusetts

Alessandro Testori  
Melanoma and muscle-cutaneous sarcomas Division, Istituto Europeo di Oncologia, Milan, Italy

Magdalena Thurin  
Program Director, Cancer Diagnosis Program, Division of Cancer Treatment and Diagnosis, NCI, NIH, Rockville, Maryland

Fernando Vidal-Vanaclocha  
Professor of Cell Biology and Human Histology, Vice Dean for Research and International Affairs and Scientific Director of the Institute of Applied Molecular Medicine (IMMA) at the CEU-San Pablo University School of Medicine, Madrid, Spain

Ena Wang  
Acting Section Head of Infectious Disease and Immunogenetics Section (IDIS); Director of Molecular Science, Department of Transfusion Medicine, CC; Associated director of Center for Human Immunology, NIH, Maryland
This CME event has been sponsored by an unrestricted grant from: